Vascular Biogenics Ltd. operating as VBL Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Vascular Biogenics Ltd. operating as VBL Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Vascular Biogenics Ltd. operating as VBL Therapeutics: 6 sponsored US clinical trials, none currently recruiting.
Vascular Biogenics Ltd. operating as VBL Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Differential Thyroid Cancer, with 1 trials.
Upper-quartile sponsor footprint
Vascular Biogenics Ltd. operating as VBL Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
NCT03398655
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
NCT02511405
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
NCT01711970
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
NCT01229865
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
NCT01260506
Study to Assess VB-201 in Patients With Psoriasis
NCT01001468
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
How the Vascular Biogenics Ltd. operating as VBL Therapeutics early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).
Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Differential Thyroid Cancer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Vascular Biogenics Ltd. operating as VBL Therapeutics: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Vascular Biogenics Ltd. operating as VBL Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Vascular Biogenics Ltd. operating as VBL Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Vascular Biogenics Ltd. operating as VBL Therapeutics or any single study.
- None of Vascular Biogenics Ltd. operating as VBL Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Differential Thyroid Cancer is the condition Vascular Biogenics Ltd. operating as VBL Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Differential Thyroid Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vascular Biogenics Ltd. operating as VBL Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.